By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.

Contact Information

Website: www.epizyme.com
Email: ir@epizyme.com
Main Phone: +1 617 229-5872
Address: 400 Technology Square
Address 2: 4th Floor
State: MA
City / Town: Cambridge
Country: US
Postal Code: 02139

Issuer Information

Exchange: NGS
CEO: Robert B. Bazemore
Employees: 304
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A